Study on the Safety of Human Oligodendrocyte Precursor Cell Transplantation in Young Animals and Its Efficacy on Myelination.
demyelinating diseases
hOPCs
myelination
toxicology
transplantation
Journal
Stem cells and development
ISSN: 1557-8534
Titre abrégé: Stem Cells Dev
Pays: United States
ID NLM: 101197107
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
pubmed:
8
4
2021
medline:
22
3
2022
entrez:
7
4
2021
Statut:
ppublish
Résumé
Oligodendrocyte precursor cells (OPCs) can differentiate into myelinating oligodendrocytes during embryonic development, thereby representing an important potential source for myelin repair or regeneration. To the best of our knowledge, there are very few OPCs from human sources (human-derived OPCs [hOPCs]). In this study, we aimed to evaluate the safety and remyelination capacity of hOPCs developed in our laboratory, transplanted into the lateral ventricles of young animals. Several acute and chronic toxicity experiments were conducted in which different doses of hOPCs were transplanted into the lateral ventricles of Sprague-Dawley rats of different ages. The toxicity, biodistribution, and tumor formation ability of the injected hOPCs were examined by evaluating the rats' vital signs, developmental indicators, neural reflexes, as well as by hematology, immunology, and pathology. In addition, the hOPCs were transplanted into the corpus callosum of the shiverer mouse to verify cell myelination efficacy. Overall, our results show that transplanted hOPCs into young mice are nontoxic to their organ function or immune system. The transplanted cells engrafted in the brain and did not appear in other organs, nor did they cause tissue proliferation or tumor formation. In terms of efficacy, the transplanted hOPCs were able to form myelin in the corpus callosum, alleviate the trembling phenotype of shiverer mice, and promote normal development. The transplantation of hOPCs is safe; they can effectively form myelin in the brain, thereby providing a theoretical basis for the future clinical transplantation of hOPCs.
Identifiants
pubmed: 33823616
doi: 10.1089/scd.2021.0012
pmc: PMC8165470
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
587-600Références
Exp Mol Med. 2011 Oct 31;43(10):596-603
pubmed: 21847008
Exp Cell Res. 2020 Oct 15;395(2):112184
pubmed: 32707134
Sci Adv. 2020 Dec 4;6(49):
pubmed: 33277253
J Neuroimmunol. 2009 Jul 25;212(1-2):74-81
pubmed: 19477025
Birth Defects Res B Dev Reprod Toxicol. 2011 Aug;92(4):292-303
pubmed: 22623020
Dev Cell. 2006 Nov;11(5):697-709
pubmed: 17084361
Regul Toxicol Pharmacol. 2020 Dec;118:104810
pubmed: 33122047
Stem Cell Reports. 2019 Aug 13;13(2):254-261
pubmed: 31378671
Nat Biotechnol. 1998 Nov;16(11):1033-9
pubmed: 9831031
Mult Scler. 2018 Aug;24(9):1243-1250
pubmed: 28675955
Int J Nanomedicine. 2017 Apr 27;12:3365-3374
pubmed: 28490876
J Neurosci. 2006 Nov 29;26(48):12497-511
pubmed: 17135412
Biol Psychiatry. 2018 Jun 1;83(11):915-923
pubmed: 29478700
Birth Defects Res B Dev Reprod Toxicol. 2010 Dec;89(6):467-73
pubmed: 20632393
J Vis Exp. 2012 Dec 20;(70):
pubmed: 23288248
Cell Transplant. 2008;17(12):1277-93
pubmed: 19364066
PLoS One. 2010 Apr 12;5(4):e10145
pubmed: 20405042
Cell Transplant. 2013;22 Suppl 1:S101-12
pubmed: 24070130
Med Hypotheses. 2009 Nov;73(5):757-9
pubmed: 19467573
Neuron. 1997 Sep;19(3):473-6
pubmed: 9331339
Neurosci Res. 2008 Aug;61(4):335-46
pubmed: 18550187
Stem Cells Int. 2016;2016:4079863
pubmed: 27429621
Annu Rev Anim Biosci. 2018 Feb 15;6:99-119
pubmed: 29237141
Stem Cells Transl Med. 2017 Oct;6(10):1917-1929
pubmed: 28834391
Stem Cell Res Ther. 2019 Aug 27;10(1):272
pubmed: 31455382
Nat Rev Neurosci. 2009 Jan;10(1):9-22
pubmed: 19096367
Cell Stem Cell. 2013 Feb 7;12(2):252-64
pubmed: 23395447
Stem Cells Dev. 2012 Jul 20;21(11):1831-7
pubmed: 22122665
Ann Neurol. 2012 Aug;72(2):224-33
pubmed: 22807310
Zhongguo Dang Dai Er Ke Za Zhi. 2017 Sep;19(9):1003-1007
pubmed: 28899472
J Neurosurg Pediatr. 2013 Jun;11(6):643-52
pubmed: 23581634
Stem Cells. 2008 Jan;26(1):254-65
pubmed: 17962704
Dev Cell. 2018 Aug 20;46(4):504-517.e7
pubmed: 30078729
Semin Cell Dev Biol. 2019 Nov;95:54-73
pubmed: 29782926
Sci Rep. 2015 Nov 09;5:16167
pubmed: 26548646
Hum Exp Toxicol. 2002 Sep-Oct;21(9-10):513-9
pubmed: 12458909
Nat Med. 2004 Jan;10(1):93-7
pubmed: 14702638
Neuroscientist. 2015 Jun;21(3):266-76
pubmed: 24722526
Glia. 2021 Mar;69(3):792-811
pubmed: 33098183
Stem Cells Dev. 2013 Sep 15;22(18):2459-76
pubmed: 23621561
Regul Toxicol Pharmacol. 2004 Jun;39(3):381-9
pubmed: 15135215
Neuropharmacology. 2003 Sep;45(4):450-60
pubmed: 12907306
Cell Stem Cell. 2008 Jun 5;2(6):553-65
pubmed: 18522848
Stem Cells. 2010 Jun;28(6):1099-106
pubmed: 20506226
Arch Neurol. 2010 Oct;67(10):1187-94
pubmed: 20937945
J Neurotrauma. 2004 Apr;21(4):429-40
pubmed: 15115592
Brain Res. 2000 Feb 28;857(1-2):141-50
pubmed: 10700561
Front Cell Neurosci. 2015 Mar 17;9:77
pubmed: 25852473
Brain Res. 2016 May 1;1638(Pt B):138-160
pubmed: 26385417
Ann Neurol. 2014 Jul;76(1):5-19
pubmed: 24916848
Sci Rep. 2018 Oct 3;8(1):14776
pubmed: 30283042
Nat Neurosci. 2001 Nov;4(11):1116-22
pubmed: 11600888
Saudi Med J. 2002 Nov;23(11):1319-23
pubmed: 12506287
Development. 2009 May;136(9):1443-52
pubmed: 19363151
Ther Innov Regul Sci. 2018 Sep;52(5):641-648
pubmed: 29714556